TP53 status determines clinical significance of ERBB2 expression in ovarian cancer

ERBB2 expression has been found in 19 to 44% of ovarian carcinomas; however, its predictive value has not been demonstrated, and trastuzumab has not found clinical application in ovarian cancer patients. We evaluated clinical significance of ERBB2 expression in relation to TP53 accumulation in ovari...

Descripción completa

Detalles Bibliográficos
Autores principales: Kupryjańczyk, J, Mądry, R, Plisiecka-Hałasa, J, Bar, J, Kraszewska, E, Ziółkowska, I, Timorek, A, Stelmachów, J, Emerich, J, Jędryka, M, Płużańska, A, Rzepka-Górska, I, Urbański, K, Zieliński, J, Markowska, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Molecular and Cellular Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409772/
https://www.ncbi.nlm.nih.gov/pubmed/15545967
http://dx.doi.org/10.1038/sj.bjc.6602238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409772/
https://www.ncbi.nlm.nih.gov/pubmed/15545967
http://dx.doi.org/10.1038/sj.bjc.6602238

Ejemplares similares